Five years into the rollout of Extended Producer Responsibility schemes for packaging, early policy experimentation is giving ...
BACKGROUND: Congenital heart disease (CHD), the most common birth defect and a leading cause of infant mortality, is ...
First-in-class oral ERAP1 inhibitor demonstrates objective response rates (ORR) of 13-36% across patients with secondary anti-PD-1 resistance or microsatellite stable colorectal cancer without liver ...
Photonic chips sit deep inside the modern internet, routing the light pulses that carry emails, videos and AI requests around ...
Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans June 1, 2026 8:00 ...
PWM relays allow engineers to go beyond simple "on-off" control to realize significant power savings and reduced heat ...
Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural ...
Marvell is becoming a top AI data center infrastructure play, boosted by NVIDIA ties and strong guidance. Read more on MRVL ...
"ASCO26: BMS and J&J debut shining multiple myeloma data" was originally created and published by Pharmaceutical Technology, ...
Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to ...
Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired ...
Discussion highlights growing importance on novel ADC payloads, and Akari’s ASCO data in KRAS-driven cancers and future ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results